We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study.
- Authors
Smith, Ashley A.; Lindley, Stephanie E.S.; Almond, Greg T.; Bergman, Noelle S.; Matz, Brad M.; Smith, Annette N.
- Abstract
Background: Greater than 90% of dogs with appendicular osteosarcoma will develop pulmonary metastasis despite the standard of care. Available treatments have limited efficacy for stage III disease. Zoledronate, a bisphosphonate, induces apoptosis of canine osteosarcoma cells and appears to modulate the tumour microenvironment. Objectives: This prospective, single institutional phase IIa trial investigated the use of single agent zoledronate in dogs with pulmonary metastases from osteosarcoma. Methods: Zoledronate was administered once monthly, and thoracic radiographs were used to assess response. Results: Eleven dogs were enrolled. Stable disease was achieved in two of eight dogs available for response assessment. The median progression‐free survival was 28 days (range: 4–93 days). The median stage III‐specific survival time was 92 days. Adverse events were reported in four dogs; two dogs developed grade III or higher toxicities. Notable adverse events included conjunctivitis, fever, hypocalcaemia, and hypophosphatemia. Conclusions: Zoledronate appears to have limited efficacy as a single agent for stage III osteosarcoma and may be associated with unexpected toxicity in this population. This clinical trial was registered on the AVMA Animal Health Studies Database (AAHSD004396).
- Subjects
OSTEOSARCOMA; PROGRESSION-free survival; TUMOR microenvironment; DATABASES; ANIMAL health
- Publication
Veterinary Medicine & Science, 2023, Vol 9, Issue 1, p59
- ISSN
2053-1095
- Publication type
Article
- DOI
10.1002/vms3.1000